News

January 07, 2016

BOSTON, Massachusetts | January 7, 2016 – Claritas Genomics, Inc., is pleased to announce that they have been granted ISO 15189 accreditation (Certificate 3712.01) by the American Association for Laboratory Accreditation (A2LA), after a thorough assessment and review of its quality management system and competence to perform over 100 molecular diagnostic tests on the Claritas menu. 

Claritas decided to pursue ISO certification shortly after spinning out of Boston Children’s Hospital in February 2013.  “We felt the complex nature of molecular diagnostics warranted the rigor...

January 05, 2016

BOSTON / PRNewswire-USNewswire/ -- Claritas Genomics, Inc., announced today the formation of a Scientific Advisory Board (SAB) comprised of physicians and scientists recognized as leading experts in the areas of medical genetics, neurology, oncology, pharmacology, translational medicine and drug development. The SAB's mission will be to provide valuable scientific and clinical insights, along with strategic guidance, as Claritas seeks to advance its pediatric precision medicine solutions for institutions around the world.

"We are honored to welcome such an outstanding...

November 17, 2015

Patrice Milos, President and CEO of Claritas Genomics, will speak at the Personalized Medicine World Conference to be held January 24-27, 2016 in Mountain View California. Dr. Milos will be a key speaker in the featured session "Diagnosis and Management of Rare Disease". This session will focus on problem solving through barriers that exist for millions of patients worldwide who have rare diseases.

Read more at the PMWC international website.

Featured Session: Diagnosis & Management of Rare...

November 16, 2015

Article initially published on STAT News
By Melissa Bailey
Guo Family
Five-year-old LamLam Guo has spent most of his life in hospitals. Since he was a baby, he has suffered from weak muscles and has had trouble eating, but doctors can’t explain why. He lies in a hospital bed in Hong Kong, wrapped in a blanket, unable to move his eyes or to breathe on his own.

His story, spread widely on Chinese social media, has caught the...

October 07, 2015

Claritas Exome-Based Tests Simplify Use of Exomes in the Clinic to Guide Precision Care for Kids

BOSTON, Massachusetts | October 7, 2015 –Today, Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel diagnostic test is the first to exploit the strengths of multiple DNA sequencing platforms simultaneously to deliver confirmed results for a patient’s clinical whole exome within 4 weeks, compared to the industry...

October 07, 2015

Boston, Massachusetts | October 7, 2015 – Claritas Genomics, Inc., will have six presentations at the American Society of Human Genetics (ASHG) running 10/6 – 10/10 in Baltimore, MD.  Claritas colleagues and collaborators from Boston Children’s Hospital and The Congenital Muscle Disease International Registry (CMDIR) will present data on the company’s innovative approach to deliver fast, rapidly confirmed, and phenotypically focused testing, demonstrating the benefits for patients, healthcare providers, and hospital systems.   

“So many rare childhood...

June 23, 2015

BOSTON, Massachusetts — Today Claritas Genomics and Genetic Alliance announced a partnership to help patients and families find and participate in relevant research opportunities that will advance understanding of individual genetic disorders and development of new therapies. In this partnership, Claritas, in collaboration with patient advocacy organizations, will use the Platform for Engaging Everyone Responsibly (PEER), created by the Genetic Alliance and Private Access, to connect the patient’s genetic test and exome results to their clinical information and enable families to...

March 24, 2015

CAMBRIDGE, MA /PRNewswire-USNewswire/ — Claritas Genomics will present data on the quality of parallel multi-technology sequencing, a comparison of the company’s phenotypically driven Pediatric Neurology Exome Assay to whole exome and panel-based approaches, three-part reports for rapid results reporting, and the clinical utility of the Neurology Exome’s tailored approach compared to other tests currently on the market.

“Gene testing is transitioning from a pick and choose artisanal approach for test selection, gene selection, variant analysis and reporting, to standardized and...

January 26, 2015

Begins 2015 with $15 Million Investment by NextCODE Health (now part of WuXi-NextCODE Genomics), Boston Children’s Hospital, Cerner Corporation and Cincinnati Children’s Hospital Medical Center

CAMBRIDGE, MA – Claritas Genomics announced today that it has secured $15 million in capital for its Series B round to expand its commercial operations, launch new next generation sequencing-based tests for diagnosis of pediatric genetic disorders and continue to build its network of clinical pediatric disease...

About Claritas

Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers. By combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions, Claritas is working to improve patient care and enable new discoveries. We are committed to the highest quality and accessibility of information and our interpretive services and unique approach to reporting set the standard for reliably and clearly communicating genetic information.

Now is the time to integrate genomics into clinical practice to inform, guide and improve medical treatment for kids around the world.